Eurofins-Cerep (ALECR.PA)

Executive Summary

Eurofins-Cerep, a subsidiary of the global Eurofins Scientific network, is a leading contract research organization (CRO) providing integrated drug discovery and development services. Specializing in pharmacology, ADME-Tox, and in vitro safety profiling, the company serves pharmaceutical, biotechnology, and agrochemical clients worldwide. Its position within the larger Eurofins ecosystem offers cross-selling opportunities and operational efficiencies, while its public listing (ALECR.PA on Euronext Paris) provides transparency and capital market access. The CRO industry benefits from structural tailwinds, including increased R&D outsourcing by pharma and biotech firms seeking to reduce costs and accelerate timelines. Eurofins-Cerep is well-positioned to capture a share of this demand due to its comprehensive service suite and reputation for quality. However, competition from other large CROs and pricing pressure remain risks. The company's estimated valuation of ~$80 million reflects its niche but stable market position. Growth is expected to be driven by new contract wins, expansion of service offerings, and leveraging Eurofins' global reach.

Upcoming Catalysts (preview)

• Q3 2026New large contract with a top-20 pharmaceutical company40% success
• Q3 2026Launch of expanded in vitro screening panel (e.g., high-throughput ADME-Tox)60% success
• Q2 2026Release of strong H1 2026 financial results showing revenue growth80% success